Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium
- Author(s)
- Han, JX; Koh, MJ; Boussi, L; Sorial, M; McCabe, SM; Peng, L; Singh, S; Eche-Ugwu, IJ; Gabler, J; Fernandez Turizo, MJ; MacVicar, CT; Garg, AR; Disciullo, A; Chopra, K; Lenart, AW; Nwodo, E; Barnes, JA; Koh, MJ; Miranda, ECM; Chiattone, CS; Stuver, RN; Horwitz, SM; Merrill, MH; Jacobsen, ED; Manni, M; Civallero, M; Skrypets, T; Lymboussaki, A; Federico, M; Kim, YR; Kim, JS; Cho, JY; Eipe, T; Shet, TDr; Epari, S; Shetty, A; Saha, S; Jain, HDr; Sengar M Md, DM; van der Weyden, C; Prince, HM; Hamouche, R; Muradashvili, T; Foss, FM; Gentilini, M; Casadei, B; Zinzani, PL; Okatani, T; Yoshida, N; Yoon, SE; Kim, WS; Panchoo, G; Mohamed, Z; Verburgh, E; Alturas, JC; Al-Mansour, M; Ford, J; Cabrera, ME; Ku, A; Bhagat, G; Ma, H; Sawas, A; Kariya, KM; Iwasaki, M; Bhanushali, F; O'Connor, OA; Marchi, E; Shen, C; Shah, D; Jain, S;
- Journal Title
- Blood Advances
- Publication Type
- Online publication before print
- Abstract
- Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and NK-cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In PTCL-NOS and ALK- ALCL, patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60, primary refractory disease, histological subtype other than AITL, extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count <LLN. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL (PIRT), in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14% (95% CI: 17.1-83.7), 23.3% (8.7-41.9), and 7% (0.4-26.9), respectively. Patients received either a "novel" single agent (SA, 35%) or cytotoxic chemotherapy (CC, 60%) for their second line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK- ALCL. Among the SA, small molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results underscore efficacy of novel drugs and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2024014674
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-28 05:45:53
Last Modified: 2024-11-28 06:29:14